Mandate

Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing

February 15, 2016

Vinge advises BioGaia AB (publ) and its subsidiary Infant Bacterial Therapeutics AB (publ) ("IBT") in connection with the proposed distribution of BioGaia’s shares in IBT to the shareholders of BioGaia. In connection with the distribution, IBT will apply for listing of the company's series B shares on Nasdaq First North. IBT is developing a drug (IBP-9414) against necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Vinge's team consists of Erik Sjöman, Dain Hård Nevonen, Ludvig Frithiof and Joel Wahlberg. Tora Hansjons advises on tax matters.

Related

Vinge has advised Vitamin Well and its majority shareholders Cinven, Bridgepoint and the founders on Vitamin Well's combination with EMPWR

Vinge has advised Vitamin Well and its majority shareholders Cinven, the founders of Vitamin Well and Bridgepoint on Vitamin Well's acquisition of EMPWR Nutrition Group from majority seller Waterland Private Equity Investments.
July 03, 2026

Vinge has advised Morrow Bank in connection with its issuances of primary capital instruments (AT1) and tier 2 capital bonds (T2)

The issuances comprised perpetual AT1 bonds of NOK 300 million with a floating coupon of 3-month NIBOR + 425 basis points and a first call date in 2031, as well as subordinated Tier 2 bonds of SEK 200 million with a floating coupon of 3-month STIBOR + 325 basis points and a first call date in 2031. The bonds are intended to be admitted to trading on Nasdaq Stockholm.
July 03, 2026

Vinge advises Wihlborgs Fastigheter in connection with the financing of property acquisition valued at SEK 13.3 billion

Vinge advises Wihlborgs Fastigheter AB (publ) in connection with the financing of the acquisition of all of Castellum’s property holdings in Malmö, Lund and Helsingborg. The financing has been secured through Danske Bank, SEB and Swedbank.
June 29, 2026